BR0207215A - Derivados de pirazolopiriminona tendo ação de inibição de pde7 - Google Patents

Derivados de pirazolopiriminona tendo ação de inibição de pde7

Info

Publication number
BR0207215A
BR0207215A BR0207215-7A BR0207215A BR0207215A BR 0207215 A BR0207215 A BR 0207215A BR 0207215 A BR0207215 A BR 0207215A BR 0207215 A BR0207215 A BR 0207215A
Authority
BR
Brazil
Prior art keywords
derivatives
pde7
pyrazolopyriminone
action
inhibition action
Prior art date
Application number
BR0207215-7A
Other languages
English (en)
Other versions
BRPI0207215B1 (pt
Inventor
Hidekazu Inoue
Hidenobu Murafuji
Yasuhiro Hayashi
Original Assignee
Daiichi Suntory Pharma Co Ltd
Daiichi Suntory Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Suntory Pharma Co Ltd, Daiichi Suntory Biomedical Res filed Critical Daiichi Suntory Pharma Co Ltd
Publication of BRPI0207215B1 publication Critical patent/BRPI0207215B1/pt
Publication of BR0207215A publication Critical patent/BR0207215A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE PIRAZOLOPIRIMIDINONA TENDO AçãO DE INIBIçãO DE PDE7". A presente invenção refere-se a derivados de pirazolopirimidinona que são expressos pela seguinte fórmula geral (IA) ou (IB): e a seguinte fórmula geral (IA') ou (IB'): onde os símbolos são como descritos na especificação, são fornecidos como compostos desejados. Estes compostos têm a ação de inibir seletivamente PDE7, desse modo aumentando o nível de cAMP intracelular e inibindo a ativação de células T. Desse modo, eles são úteis para prevenção e tratamento de várias doenças alérgicas e doenças inflamatórias ou imunológicas.
BR0207215-7A 2001-12-13 2002-12-13 Derivados de pirazolopiriminona tendo ação de inibição de pde7 BR0207215A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001-380483 2001-12-13
JP2001380483 2001-12-13
PCT/JP2002/013083 WO2003053975A1 (fr) 2001-12-13 2002-12-13 Derives de pyrazolopyrimidinone possedant une activite inhibitrice de pde7

Publications (2)

Publication Number Publication Date
BRPI0207215B1 BRPI0207215B1 (pt) 2003-07-03
BR0207215A true BR0207215A (pt) 2004-02-10

Family

ID=19187176

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0207215A BRPI0207215B8 (pt) 2001-12-13 2002-12-13 Derivados de pirazolopirimidinona tendo ação de inibição de pde7
BR0207215-7A BR0207215A (pt) 2001-12-13 2002-12-13 Derivados de pirazolopiriminona tendo ação de inibição de pde7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0207215A BRPI0207215B8 (pt) 2001-12-13 2002-12-13 Derivados de pirazolopirimidinona tendo ação de inibição de pde7

Country Status (12)

Country Link
US (1) US7268128B2 (pt)
EP (1) EP1454897B1 (pt)
JP (1) JP4312603B2 (pt)
KR (1) KR100929513B1 (pt)
CN (1) CN1264843C (pt)
AT (1) ATE375347T1 (pt)
BR (2) BRPI0207215B8 (pt)
CA (1) CA2439784C (pt)
DE (1) DE60222931T2 (pt)
ES (1) ES2294189T3 (pt)
HU (1) HU228316B1 (pt)
WO (1) WO2003053975A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006219373A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体
DE102004027871B3 (de) * 2004-06-08 2006-03-16 Lanxess Deutschland Gmbh Verfahren zur Herstellung von 10α-[4'-(S,S-Dioxothiomorpholin-1'-yl)]-10-desoxo-10-dihydroartemisinin
CN1976938B (zh) * 2004-07-01 2012-08-15 第一三共株式会社 具有pde7抑制活性的噻吩并吡唑衍生物
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AR058071A1 (es) * 2005-10-03 2008-01-23 Astrazeneca Ab Derivados de dihidropirazolo (3,4-e)(1,4)diazepina. procesos de obtencion y composiciones farmaceuticas.
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN1966506A (zh) * 2005-11-17 2007-05-23 上海特化医药科技有限公司 吡唑并嘧啶酮衍生物及其制备方法和用途
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20090137549A1 (en) * 2006-11-09 2009-05-28 Paul John Edward Novel compounds useful for the treatment of degenerative & inflamatory diseases
US20080242661A1 (en) * 2006-12-11 2008-10-02 Graeme James Dykes Novel compounds useful for the treatment of degenerative & inflammatory diseases
US20080260643A1 (en) * 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
EA200901488A1 (ru) * 2007-05-09 2010-04-30 Новартис Аг Замещенные имидазолопиридазины, как ингибиторы липидкиназы
WO2009157423A1 (ja) 2008-06-24 2009-12-30 財団法人乙卯研究所 縮合環を有するオキサゾリジノン誘導体
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011056440A1 (en) 2009-10-27 2011-05-12 Boehringer Ingelheim International Gmbh Heterocyclic compounds as ccr1 receptor antagonists
AU2011326173B2 (en) * 2010-11-08 2015-08-27 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP6986972B2 (ja) 2015-06-18 2021-12-22 エイティナイン バイオ リミテッド 置換４−ベンジル及び４−ベンゾイルピペリジン誘導体
ES2821049T3 (es) 2015-06-18 2021-04-23 89Bio Ltd Derivados de piperidina 1,4 sustituidos
DK3356345T3 (da) * 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
MX2019007803A (es) * 2016-12-28 2019-08-29 Dart Neuroscience Llc Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2).
ES2902365T3 (es) 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
WO2024038090A1 (en) 2022-08-18 2024-02-22 Mitodicure Gmbh Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501480A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
JP3713783B2 (ja) 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
DE59803108D1 (de) * 1997-11-12 2002-03-21 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
AU4589800A (en) * 1999-05-05 2000-11-21 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7inhibitors
DE19950647A1 (de) * 1999-10-21 2001-04-26 Merck Patent Gmbh Imidazolderivate als Phosphodiesterase VII-Hemmer
DE19953025A1 (de) 1999-11-04 2001-05-10 Merck Patent Gmbh Pyrrolderivate als Phosphodiesterase VII-Hemmer
DE19953414A1 (de) * 1999-11-06 2001-05-10 Merck Patent Gmbh Imidazopyridinderivate als Phospodiesterase VII-Hemmer

Also Published As

Publication number Publication date
US20050148604A1 (en) 2005-07-07
HUP0402171A2 (hu) 2005-02-28
KR100929513B1 (ko) 2009-12-03
ES2294189T3 (es) 2008-04-01
US7268128B2 (en) 2007-09-11
DE60222931D1 (de) 2007-11-22
CN1264843C (zh) 2006-07-19
WO2003053975A1 (fr) 2003-07-03
BRPI0207215B8 (pt) 2022-11-01
KR20040065156A (ko) 2004-07-21
BRPI0207215B1 (pt) 2003-07-03
EP1454897B1 (en) 2007-10-10
EP1454897A1 (en) 2004-09-08
DE60222931T2 (de) 2008-07-10
HU228316B1 (en) 2013-03-28
JP4312603B2 (ja) 2009-08-12
CA2439784A1 (en) 2003-07-03
ATE375347T1 (de) 2007-10-15
JPWO2003053975A1 (ja) 2005-04-28
CA2439784C (en) 2010-11-02
EP1454897A4 (en) 2005-11-23
HUP0402171A3 (en) 2008-08-28
CN1533392A (zh) 2004-09-29

Similar Documents

Publication Publication Date Title
BR0207215A (pt) Derivados de pirazolopiriminona tendo ação de inibição de pde7
BRPI0518406A2 (pt) composiÇÕes tendo uma alta eficÁcia antiviral e antibacteriana
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
BR0208373A (pt) Inibidores da tirosina cinase
BR0115452A (pt) Compostos tendo atividade fungicida e processos para fabricação e uso dos mesmos
HK1114556A1 (en) External skin agent comprising modified clay for preventing inflammation
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BRPI0512916A (pt) derivado de tienopirazol tendo atividade inibidora de pde 7
BR0215052A (pt) Composições acaricidas e métodos
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
CY1108808T1 (el) Ενωσεις μοτιλιδης
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR0111358A (pt) Compostos de tioacetamida e seu uso
ECSP034924A (es) Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5]dec-2-eno
EA200801859A1 (ru) Неводная композиция стабильного витамина "c", способ ее приготовления и применения
BRPI0415179A (pt) derivados de amida como ligandos de canal de ìon e composições farmacêuticas e métodos de empregar as mesmas
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
BRPI0413742A (pt) derivados de mitoquinona usados como antioxidantes mitocondrialmente alvejados
DK1483246T3 (da) 5-Substituerede alkylaminopyrazolderivater som pesticider
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BRPI0715198A8 (pt) Composição de perfume, seu uso, método e artigo adequado para prevenção ou alívio de mau odor da urina, e produtos para consumidores
CU23348A3 (es) Procedimiento para la filtración y estabilización de líquidos acuosos

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: DAIICHI SUNTORY PHARMA CO., LTD. (JP) , DAIICHI SU

Free format text: A FIM DE ATENDER A PETICAO DE TRANSFERENCIA NO 020050044955/RJ DE 02/06/2005, ESCLARECA A DIVERGENCIA ENTRE O NOME DO TITULAR E DA EMPRESA CEDENTE.

B25A Requested transfer of rights approved

Owner name: DAIICHI SUNTORY PHARMA CO., LTD. (JP)

Free format text: TRANSFERIDO POR INCORPORACAO DE: DAIICHI SUNTORY BIOMEDICAL RESEARCH LTD.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: DAIICHI SUNTORY PHARMA CO., LTD. (JP)

Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO DE ALTERACAO DE NOME NO 020050146800/RJ DE 14/12/2005, QUEIRA APRESENTAR TRADUCAO DO DOCUMENTO DE ALTERACAO DA DENOMINACAO SOCIAL DA REQUERENTE.

B25D Requested change of name of applicant approved

Owner name: DAIICHI ASUBIO PHARMA CO., LTD. (JP)

Free format text: ALTERADO DE: DAIICHI SUNTORY PHARMA CO., LTD.

B25G Requested change of headquarter approved

Owner name: DAIICHI ASUBIO PHARMA CO., LTD. (JP)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050146800/RJ DE 14/12/2005.

B25D Requested change of name of applicant approved

Owner name: ASUBIO PHARMA CO., LTD. (JP)

Free format text: ALTERADO DE: DAIICHI ASUBIO PHARMA CO., LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP)

Free format text: TRANSFERIDO POR FUSAO DE: ASUBIO PHARMA CO., LTD.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/12/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2629 DE 25/05/2021, QUANTO AO ITEM (73) ENDERECO DO TITULAR.